Actualités

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical Services recently reported strong first-quarter 2026 results, highlighting robust growth in biologics-related high-value components and self-injection delivery devices, and raised its full-year 2026 revenue and adjusted EPS guidance. The company emphasized its role as a critical part of injectable-drug infrastructure rather than a conventional packaging supplier, underlining how its specialized high-value products support complex biologic therapies. Next, we’ll examine...